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ABSTRACT
Barrier-to-autointegration factor (BAF) is a DNA binding protein with multiple cellular functions, including the ability to act as
a potent defense against vaccinia virus infection. This antiviral function involves BAF’s ability to condense double-stranded
DNA and subsequently prevent viral DNA replication. In recent years, it has become increasingly evident that dynamic phos-
phorylation involving the vaccinia virus B1 kinase and cellular enzymes is likely a key regulator of multiple BAF functions; how-
ever, the precise mechanisms are poorly understood. Here we analyzed how phosphorylation impacts BAF’s DNA binding, sub-
cellular localization, dimerization, and antipoxviral activity through the characterization of BAF phosphomimetic and
unphosphorylatable mutants. Our studies demonstrate that increased phosphorylation enhances BAF’s mobilization from the
nucleus to the cytosol, while dephosphorylation restricts BAF to the nucleus. Phosphorylation also impairs both BAF’s dimeriza-
tion and its DNA binding activity. Furthermore, our studies of BAF’s antiviral activity revealed that hyperphosphorylated BAF is
unable to suppress viral DNA replication or virus production. Interestingly, the unphosphorylatable BAF mutant, which is capa-
ble of binding DNA but localizes predominantly to the nucleus, was also incapable of suppressing viral replication. Thus, both
DNA binding and localization are important determinants of BAF’s antiviral function. Finally, our examination of how phos-
phatases are involved in regulating BAF revealed that PP2A dephosphorylates BAF during vaccinia infection, thus counterbal-
ancing the activity of the B1 kinase. Altogether, these data demonstrate that phosphoregulation of BAF by viral and cellular en-
zymes modulates this protein at multiple molecular levels, thus determining its effectiveness as an antiviral factor and likely
other functions as well.
IMPORTANCE
The barrier-to-autointegration factor (BAF) contributes to cellular genomic integrity in multiple ways, the best characterized of
which are as a host defense against cytoplasmic DNA and as a regulator of mitotic nuclear reassembly. Although dynamic phos-
phorylation involving both viral and cellular enzymes is likely a key regulator of multiple BAF functions, the precise mechanisms
involved are poorly understood. Here we demonstrate that phosphorylation coordinately regulates BAF’s DNA binding, subcel-
lular localization, dimerization, and antipoxviral activity. Overall, our findings provide new insights into how phosphoregula-
tion of BAF modulates this protein at multiple levels and governs its effectiveness as an antiviral factor against foreign DNA.
Barrier-to-autointegration factor (BAF/BANF1) is an essential,highly conserved metazoan protein with multiple functions
linked to maintaining the integrity of the cellular genome. BAF
can interact with double-stranded DNA in a sequence-indepen-
dent manner, homodimerize to crossbridge DNA, and form high-
er-order nucleoprotein complexes (1–4). BAF also interacts with
many cellular proteins, including LAP2/emerin/MAN1 (LEM)
domain proteins that reside in the nuclear envelope, histones,
lamins, transcription factors, and DNA damage response (DDR)
proteins (5–10). Using these interactions, BAF is thought to act as a
tethering protein to bring together chromatin DNA and LEM pro-
teins during late stages of mitosis when the nuclear envelope (NE) is
being reassembled. The importance of BAF’s role during mitosis is
underscored by evidence that misregulation of these BAF-dependent
processes leads to chromosome segregation and NE defects, mislocal-
ization of LEM proteins, and embryonic lethality in Caenorhabditis
elegans and Drosophila melanogaster (11–14).
An additional mechanism through which BAF acts to protect
genomic integrity is as a host defense factor against foreign DNA
in the cytoplasm. BAF was first identified as a host protein that
targets invading genomes when it was copurified as a component
of the proviral preintegration complex (PIC). In those studies it
was observed that BAF can prevent suicidal autointegration of
retroviral DNA in vitro (15, 16). The ability of BAF to condense
DNA contributes to the compaction of viral DNA within the pre-
integration complex, thus protecting viral DNA from autointe-
gration in vitro (2, 16, 17). Interestingly, the DNA binding/com-
paction activity of BAF also allows it to be capable of potent
antiviral activity against vaccinia virus.
Poxviruses are large and complex DNA viruses that are patho-
genic to human and animals. Vaccinia virus, the prototypical
member of this family, exhibits significant autonomy from the
host cell, as demonstrated by its ability to complete its entire life
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cycle in the cytoplasm of infected cells. Such autonomy is attrib-
uted to the large poxviral genome, which encodes essential repli-
cation and transcription proteins (18, 19). One of these essential
proteins is the B1 Ser/Thr kinase, which is expressed early in the
viral life cycle and performs functions in viral DNA replication
and intermediate gene expression (20–26). The temperature-sen-
sitive mutant viruses Cts2 and Cts25 harbor point mutations
within the B1 locus and serve as critical tools for gaining insights
about B1’s functions. For example, using the Cts2 virus, it was
determined that a primary function of B1 is to phosphorylate BAF,
thereby inactivating its DNA binding capability. Both in vitro and
in vivo data support that B1 can directly phosphorylate BAF at
Thr2, Thr3, and Ser4 at BAF’s N terminus (27, 28). If not phos-
phorylated by B1, BAF localizes to the sites of viral DNA and
interferes with genome replication (27, 29) and transcription (25),
thereby leading to a sharp reduction in the number of viral prog-
eny produced (29).
Interestingly, the cell also modulates BAF phosphorylation at
its N terminus via both kinases and phosphatases of its own. For
example, BAF is a substrate of the cellular vaccinia-related kinases
(VRKs) (28, 30–33) and protein phosphatases PP2A and PP4 (32,
34). These enzymes are critical regulators of BAF’s mitotic func-
tion, controlling its interaction with DNA and other proteins (28,
31, 32, 35). However, there are also data that VRK1 can inhibit
BAF’s association with retroviral PICs in vitro (36), suggesting that
cellular enzymes may impact not only BAF’s mitotic function but
its effectiveness in binding to foreign DNA as well.
Here we further explored the impact of BAF phosphorylation
on its antipoxviral activity. Specifically, we tested the hypothesis
that multiple properties of BAF are impacted by its phosphoryla-
tion state, thereby regulating BAF’s antiviral activity through in-
terconnected mechanisms involving phosphorylation, DNA
binding, and cellular localization. Through the studies of cells sta-
bly expressing BAF phosphorylation mutants, we demonstrate
that BAF phosphomimetic mutants accumulate in the cytoplasm
but lack DNA binding activity and thus cannot suppress viral
DNA replication and production of the Cts2 B1-deficient virus.
Strikingly, the absence of suppression is also observed in a non-
phosphorylatable BAF mutant that is fully capable of binding
DNA but adopts a predominantly nuclear localization. Further-
more, we confirm that PP2A is a BAF phosphatase, and we provide
evidence that it and/or other phosphatases dephosphorylate BAF
in the cytoplasm. Together, these data reveal that phosphoregula-
tion of BAF by both viral and cellular enzymes modulates this
protein at multiple molecular levels, thus determining its effec-
tiveness as an antiviral effector and likely other functions as well.
MATERIALS AND METHODS
Cell culture. African green monkey kidney CV-1 cells (Flp-In-CV-1 cells)
were obtained from Life Technologies (catalog number R752-07) and
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS) (Atlanta Biologicals) and pen-
icillin-streptomycin and incubated at 37°C in a 5% CO2 atmosphere.
Mutagenesis and cloning of BAF mutants. To construct expression
vectors for 1 FLAG-tagged BAF (short hairpin RNA [shRNA] resistant)
and 1 FLAG-tagged MAAAQ (shRNA resistant), pcDNA5/FRT/TO/
3FLAG-BAF (27) and pcDNA5/FRT/TO/3FLAG-MAAAQ (29) were
used as templates for mutagenesis by overlapping PCR using outside
primers Bam Kozak 1Flag (5=-CTCGAGGGATCCGCCACCATGGAT
TACAAGGATGACGATGAC-3=) and BAF BamHI 3= (5=-GCAGGATCC
TCACAAGAAGGCGTCGCAC-3=) and internal mutagenesis primers
BAF resistant F (5=-GACAAGGCTTATGTGGTCCTTGGCCAG-3=) and
BAF resistant R (5=-CTGGCCAAGGACCACATAAGCCTTGTC-3=).
PCR products were BamHI digested and ligated to BamHI-digested
pHAGE-HYG-MCS (pHM) lentiviral vector (a generous gift from Paula
Traktman, Medical College of Wisconsin) to generate pHM/HYG/
1FLAG-BAF and pHM/HYG/1FLAG-MAAAQ.
To construct expression vectors introducing the amino acid muta-
tions MTTDQ (S4D) and MDDDQ (T2D/T3D/S4D), pHM/HYG/
1FLAG-BAF was used as a template for overlapping PCR using outside
primers Bam Kozak 1Flag and BAF BamHI 3= and internal mutagenesis
primers pair Flag-MTTDQ-F (5=-GACAAGCTCATGACAACCGACCA
AAAGCACCGAGAC-3=) and Flag-MTTDQ-R (5=-GGTCGGTTGTCAT
GAGCTTGTCATCGTCATCCTTGTAATCG-3=) or Flag-MDDDQ-F
(5=-GACAAGCTCATGGACGACGACCAAAAGCACCGAGAC-3=) and
Flag-MDDDQ-R (5=-GGTCGTCGTCCATGAGCTTGTCATCGTCATC
CTTGTAATCG-3=). PCR products were BamHI digested and ligated to
BamHI-digested pHAGE-HYG-MCS (pHM) vector. Each clone was ver-
ified by restriction digestion and DNA sequencing.
Production of stably expressing cells. Each lentiviral vector carrying
BAF and BAF mutants was used to generate lentivirus as previously de-
scribed (29). The stable overexpression of BAF in CV1 cells was then
performed by transducing cells using these lentivirus preparations ex-
pressing 1 FLAG-BAF or BAF mutants. For transduction, CV-1 cells
were seeded in 35-mm dishes at 0.4  106 per well. The next day, me-
dium was replaced with 1 ml of lentivirus supernatant and left for 24 h.
Medium was then replaced with fresh medium and left for an additional
24 h. Cells were then passaged in medium containing 200 g/ml of hy-
gromycin to select for stable lentiviral integration.
The stable depletion of BAF was performed using a BAF shRNA or
scrambled shRNA (control) as previously described in (29). Cells were
then passaged in medium containing 10g/ml of puromycin to select for
stable lentiviral integration. For some experiments, the stable overexpres-
sion of BAF and its mutants in shBAF cells was performed by further
transducing shBAF cells with lentivirus expressing 1 FLAG-BAF or its
mutants while shControl cells were further transduced with empty vector
pHM-HYG-MCS as a control. Transduced cells were selected with both
200 g/ml of hygromycin and 10 g/ml of puromycin.
Virus infections and viral yield assay. The wild-type (WT) vaccinia
virus (WR strain) and the B1-deficient Cts2 virus (20) were used. For viral
DNA replication, viral titer determination, and immunoblotting, CV1
cells (1  106) were infected with WT or Cts2 virus at a multiplicity of
infection (MOI) of 5 at 40°C for 24 h. The next day, cells were harvested
onto 1 ml phosphate-buffered saline (PBS) (10 mM Na2HPO4 · 7H2O, 1
mM KH2PO4, 2 mM KCl, 140 mM NaCl, pH 7.4). Cells were aliquoted
(200l for viral DNA replication, 400l for viral titer determination, and
400 l for immunoblotting) prior to the appropriate analyses performed
on each aliquot. For immunofluorescence, CV1 cells were infected with
Cts2 vaccinia virus at an MOI of 5 at 32°C for 16 h, followed by a shift to
40°C for 3 h.
For viral yield assays, following cell harvest, cells were pelleted and cell
pellets were resuspended in 10 mM Tris (pH 9). Samples were freeze-
thawed three times prior to titration on BSC40 cells at 32°C.
Immunoprecipitation analysis. CV1 cells (1  106) were harvested
and pelleted at 8,000 g for 10 min at 4°C. Cells were then lysed in 1 ml of
cell lysis buffer (50 mM Tris-HCl [pH 6.8], 2 mM MgCl2, 200 mM NaCl,
and 0.2% Triton X-100, supplemented with Complete protease inhibitor
[Roche], PhosSTOP phosphatase inhibitor [Roche], and 10 units benzo-
nase) on ice for 30 min, followed by centrifugation at 8,000 g for 10 min
at 4°C. The supernatant was transferred to a new tube, followed by an-
other centrifugation at 10,000 g for 10 min at 4°C. Next, this superna-
tant was incubated with 2.5 g of mouse anti-FLAG M2 antibody on an
end-over-end rotator for 2 h at 4°C, at which point 10 l of magnetic
Dynabeads protein G (Life Technologies) equivalent to a 5-l bead vol-
ume was added and rotated overnight at 4°C. The next day, beads were
washed 4 times in Tris-buffered saline (TBS) (20 mM Tris-HCl [pH 7.4],
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150 mM NaCl). Bound proteins were eluted by the addition of 120 l of
2 SDS sample buffer (100 mM Tris [pH 6.8], 2% -mercaptoethanol,
2% SDS, 32.5% glycerol, bromophenol blue).
Subcellular fractionation. Subcellular fractionations were performed
as described previously (37) with modifications. Cell pellets obtained
from CV-1 cells (1.2 106) upon harvest and centrifugation at 500 g for
10 min at 4°C were treated with cell lysis buffer (50 mM Tris-HCl [pH
6.8], 2 mM MgCl2, 150 mM NaCl, and 0.5% saponin, supplemented with
Complete protease inhibitor [Roche] and PhosSTOP phosphatase inhib-
itor [Roche]) on ice for 10 min. Soluble cytoplasmic fractions were col-
lected following centrifugation at 500 g at 4°C for 10 min. The insoluble
pellets were further treated with Triton X-100 lysis buffer (50 mM Tris-
HCl [pH 6.8], 2 mM MgCl2, 75 mM NaCl, 0.2% Triton X-100, 0.1% SDS,
1 Complete protease inhibitor [Roche], PhosSTOP phosphatase inhib-
itor [Roche]) on ice for 10 min. Soluble nuclear fractions were collected
following centrifugation at 10,000 g at 4°C for 10 min. To each fraction,
2 SDS sample buffer was added, followed by loading for SDS-PAGE.
Phosphatase inhibitor treatment. Calyculin A (Sigma C5552 or Santa
Cruz 24000) and okadaic acid (SantaCruz 3513) stock and serial dilution
solutions were prepared in dimethyl sulfoxide (DMSO). CV-1 cells (1.2
106) were treated with phosphatase inhibitor diluted in DMEM-FBS (final
DMSO concentration of 1%) at 37°C for 2 h. Cells were then harvested by
scraping, washed in PBS, and lysed in 2 SDS sample buffer prior to
loading for SDS-PAGE.
Plasmid transfection. For transfection experiments, pG8-luciferase
plasmid (a generous gift from B. Moss, NIAID, Bethesda, MD) and
pUC19 plasmid were used. For chromatin immunoprecipitation (ChIP)
experiments, CV-1 cells (6 106) were transfected with 150 ng pG8-Luc
plasmid for 24 h by using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s protocol. For immunofluorescence, CV-1 cells were
transfected with 1 g of pUC19 plasmid for 24 h.
Immunofluorescence. Cells were fixed in 4% paraformaldehyde in 1
PBS at room temperature for 20 min. Following fixation, cells were perme-
abilized with 0.2% Triton X-100 in PBS for 10 min at room temperature. Cells
were then incubated with mouse anti-FLAG M2 antibody (Sigma) and/or
rabbit anti-I3 (1:500) for 1 h at room temperature. Following washing with
PBS, cells were then incubated with Alexa Fluor 488-conjugated goat anti-
mouse-488 (Invitrogen) in PBS and/or Alexa Fluor 594-conjugated goat anti-
rabbit-594 (Invitrogen) in PBS for 1 h at room temperature. Cells were then
washed in PBS, and DNA was stained with DAPI (4=,6=-diamidino-2-phe-
nylindole). Fluorescence images were taken by indirect fluorescence on an
inverted (Olympus IX 81) confocal microscope, and final images were ob-
tained by pseudocoloring using ImageJ software.
Immunoblotting analysis. CV-1 cells (1.2  106) were freshly col-
lected, pelleted, and resuspended in 300 l of SDS sample buffer supple-
mented with 10 units of benzonase as described previously (25). Lysate
volumes equivalent to 105 cells were resolved by 18% SDS-PAGE followed
by protein transfer to polyvinylidene difluoride (PVDF) membranes
overnight. Blots were then incubated with the appropriate antibodies
prior to signal development with chemiluminescent reagents. Quantifica-
tions of the chemiluminescence signal were performed by using a Bio-Rad
ChemiDoc XRS instrument and Bio-Rad ImageLab software. The pri-
mary antibodies used were as follows: GAPDH (glyceraldehyde-3-phos-
phate dehydrogenase), 1:200 (Santa Cruz Biotechnology sc-25778); -tu-
bulin, 1:20,000 (Sigma T7816); FLAG M2 monoclonal, 1:8,000 (Sigma
F1804); BAF, 1:5,000 (custom antibody); phospho-BAF (Ser4) antibody,
1:1500 (custom antibody); PP1 (E9) monoclonal, 1:200 (Santa Cruz Bio-
technology sc-7482); PP1 monoclonal, 1:5,000 (Epitomics 2029-1);
PP2A monoclonal, 1:1,000 (Millipore 05-421); PPP4C, 1:500 (Bethyl Lab-
oratories A300-835A); and PPP6C, 1:1,000 (Bethyl Laboratories A300-
844A).
siRNA depletion. Small interfering RNAs (siRNAs) against PP1,
PP2A, PP4, and PP6 and nontargeting siRNAs were designed and ordered
from Dharmacon. The siRNA sense sequences were as follows: PP1,
5=-CCGCAUCUACGGUUUCUACUU-3=; PP1, 5=-UUAUGAGACCU
ACUGAUGUUU-3=; PP1, 5=-GCAUGAUUUGGAUCUUAUAUU-3=;
PP2A, 5=-CGUGCAAGAGGUUCGAUGUUU-3=; PP2A/PPP2CB, 5=-
GCGAGAAGGCAAAGGAAAUUU-3=; PPP4C, 5=-GACAAUUGACCGA
AAGCAAUU-3=; PPP6C, 5=-GCACGAAGGCUAUAAAUUUUU-3=; and
scrambled siRNA (siControl), 5=-CAGUCGCGUUUGCGACUGGUU-
3=. CV-1 cells were transfected with 50 nM siRNAs using RNAimax (Life
Technologies) as per the manufacturer’s protocol. Depletion was mea-
sured by both quantitative PCR (qPCR) and immunoblotting. For qPCR,
RNA was extracted at 48 h posttransfection. For immunoblotting, protein
depletions were analyzed at 72 h posttransfection. All infection experi-
ments were performed following 72 h of siRNA treatment.
ChIP Assays. Chromatin immunoprecipitation was performed as de-
scribed previously (25) with the following slight modification. After over-
night incubation of lysates and antibodies and 2 h of incubation of Dyna-
beads, beads were washed 3 times with final wash buffer (20 mM Tris-HCl
[pH 8.0], 500 mM NaCl, 2 mM EDTA [pH 8], 1% Triton X-100, and 0.1%
SDS), followed by elution of bound complexes. Immunoprecipitated and
input materials were analyzed by quantitative PCR (StepOne Plus real-
time PCR; Applied Biosystems).
DNA/RNA purification and qPCR. Viral DNA was extracted using
the GeneJET whole-blood genomic DNA purification minikit (Thermo
Scientific K0782) or QIAamp DNA blood minikit (Qiagen 51106). For
ChIP analysis, DNA was purified by glass bead purification using agarose
dissolving buffer (Zymo Research D4001-1-50).
qPCR was performed using SYBR green PCR Master Mix (Applied
Biosystems 4309155) or Bio-Rad iTaq Universal SYBR green Supermix
(172-5121). Serial dilutions were included in each qPCR run to develop a
standard curve and determine the PCR efficiency of the primer sets in that
experiment set. qPCR analyses were performed using 1 l of purified
DNA and 1 M each primer as follows: vaccinia HA F (5=-CATCATCTG
GAATTGTCACTACTAAA-3=) and R (5=-ACGGCCGACAATATAATTA
ATGC-3=), human GAPDH F (5=-GCAAATTCCATGGCACCGT-3=)
and R (5=-TCGCCCCACTTGATTTTGG-3=), and G8Pro ChIP Fwd (5=-
CTTCGTGGATCCTGTAGAACG-3=) and G8Pro ChIP Rev (5=-CCATC
TTCCAGCGGATAGAATG-3=).
To analyze mRNA transcript levels following siRNA depletion, RNA
was isolated from cells by using RiboPure kit (Ambion, Life Technologies,
AM1924). cDNA was then synthesized by using a high-capacity cDNA
reverse transcription kit (Invitrogen, Life Technologies, 4368814). qPCR
analyses were further performed using 2 l of cDNA (40 to 50 ng) and 1
M each primer as follows: PPP1CA (PP1) F (5=-GAGACCATCTGCC
TGCTGCT-3=) and R (5=-CAGTTTGATGTTGTAGCGTCTCTTG-3=),
PPP1CB (PP1) F (5=-CGAGTTTGATAATGCTGGTGGAATG-3=) and
R (5=-GCTGTTCGAGTTGGAGTGAC-3=), PPP1CC (PP1) F (5=-AAA
GAGGCAGTTGGTCACTCTG-3=) and R (5=-TTACAGGTCTCGTGGC
ATTTGG-3=), and PPP2CA (PP2A) F (5=-AGTTACACTGCTTGTAGC
TCTTAAGGT-3=) and R (5=-GCTCTCATGATTCCCTCGAA-3=).
Statistics. Error bars shown represent standard deviations from the
mean. The P values indicated were calculated using the Student t test.
RESULTS
Stable expression of BAF phosphorylation mutants in CV1 cells.
We hypothesize that BAF’s antiviral activity depends on the inter-
woven regulation of its phosphorylation, cellular localization, and
other molecular properties. Here we examined the impact of BAF
phosphorylation on its localization, DNA binding, dimerization,
and antipoxviral activity using cells stably expressing BAF phos-
phorylation mutants. Specifically, we changed the amino acids at
one or several known BAF phosphorylation sites (Thr2, Thr3, and
Ser4) to either an alanine (A) (a nonpolar and uncharged amino
acid) or an aspartic acid (D) (a negatively charged amino acid).
We designated these mutants MAAAQ, MTTDQ, and MDDDQ
(Fig. 1A). Each construct, including WT BAF, also contains a sin-
gle FLAG epitope tag at its N terminus and was expressed using a
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lentiviral expression system which allows for stable integration
into the host genome and hygromycin resistance. Following anti-
biotic selection of transduced cells, expression of endogenous BAF
and each FLAG-BAF mutant was verified by immunoblot analysis
with an anti-BAF antibody (Fig. 1B). As described in previous
studies, endogenous BAF proteins can be separated into two or
three distinct protein bands of around 10 kDa in size (27, 28, 36).
Each distinct band corresponds to certain BAF phosphorylation
states in which the protein migration decreases as BAF becomes
more phosphorylated. Thus, the unphosphorylated form migrates
the fastest, followed by the Ser4-phosphorylated form and finally
the hyperphosphorylated (phosphorylated at all three residues)
form. Consistent with these migration patterns, the 1 FLAG-
tagged WT BAF and mutant proteins also displayed distinct elec-
trophoretic mobilities, which demonstrated that tagging the pro-
tein with a single FLAG epitope still allows us to examine the BAF
phosphorylation pattern via immunoblotting (Fig. 1B). All mu-
tant and WT BAF proteins, averaging from three separate trans-
ductions, were expressed at 3.8- to 5.5-fold-higher levels than the
endogenous BAF proteins (Fig. 1C). In addition, the growth rate
of each of these CV1 cells was comparable to that of cells express-
ing an empty-vector control (apparent doubling times ranged be-
tween 30 and 31 h), with the exception of MAAAQ (doubling
times of 34.8 h; 15% reduction compared to control). Overall,
these data confirm the expression of our BAF phosphomutants.
Unphosphorylated BAF is retained in the nucleus, while
phosphorylated BAF is localized in the cytoplasm. Previous
studies have suggested that BAF’s subcellular localization depends
on its phosphorylation states. In those studies, transient coexpres-
sion of green fluorescent protein (GFP)-WT BAF and its kinase
3 FLAG-VRK1 led to relocalization of GFP-WT BAF to the cy-
tosol in U2OS cells (28). In contrast, the nonphosphorylatable
mutant GFP-MAAAQ remained nuclear despite VRK1 overex-
pression (28). To further investigate how posttranslational mod-
ification affects BAF’s location, we began by analyzing the subcel-
lular distribution of our stably expressed mutant proteins by
immunofluorescence assay using an anti-FLAG antibody. Like en-
dogenous BAF (14, 29, 38–40), WT BAF is expressed in the nu-
cleus, nuclear envelope, and cytoplasm (Fig. 2B), and such local-
ization is also consistent with the published results on GFP-tagged
and 3 FLAG-tagged BAF (27, 28, 30, 41). With regard to the
mutant BAF, we found that MAAAQ is found almost exclusively
in the nucleus (Fig. 2C), while both our phosphomimetic mutants
MTTDQ and MDDDQ displayed a cellular distribution similar to
that of WT BAF (Fig. 2D and E). Next, to complement our immu-
nofluorescence analyses of the subcellular distribution of these
mutant proteins, we also performed subcellular fractionation as-
says followed by immunoblotting analyses. First, cells were lysed
with the mild detergent saponin to release cytoplasmic proteins,
followed by treatment of the saponin-insoluble fraction with Tri-
ton X-100 to release nuclear proteins (37). As expected, WT BAF
was distributed in both the cytoplasm (42.4%) and the nucleus
FIG 1 Stable expression of BAF phosphorylation mutants in CV1 cells. (A)
Point mutations were introduced into BAF N-terminal residue Thr2, Thr3, or
Ser4 as indicated in the amino acid alignment. The residues were mutated to A
(alanine) or D (aspartic acid). (B) Representative Western blot analysis of
whole-cell lysates from cells stably expressing WT BAF and BAF mutants.
Anti-BAF antibody recognizes endogenous BAF protein (arrowheads) and
FLAG-tagged proteins (bracketed). Anti-GAPDH antibody was used as a load-
ing control. (C) Quantification of protein expression relative to empty-vector
control cells. Data were obtained from three independent transduction exper-
iments. Error bars represent standard deviations.
FIG 2 Subcellular distribution of BAF phosphorylation mutants. (A to E)
Immunofluorescence analyses of WT BAF and BAF mutants with an anti-
FLAG antibody (Alexa Fluor 488 conjugated). Nuclei were visualized by DAPI
staining. Cells expressing empty vector (A), WT BAF (B), MAAAQ (C),
MTTDQ (D), and MDDDQ (E) were analyzed. Scale bar, 50 m. (F) Subcel-
lular fractionation analyses of cells indicated in panels A to E. Fractionated cell
lysates were analyzed by immunoblotting with an anti-FLAG antibody and
quantified with ImageLab software (Bio-Rad). The percent protein distribu-
tion was derived from the amount of protein in either the cytosol (gray bars) or
nuclear (black bars) fraction relative to the total protein in both fractions (n
3). Error bars represent standard deviations.
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(57.6%) (Fig. 2F). In contrast, more than 90% of MAAAQ was
distributed to the Triton X-100-soluble nuclear fraction (Fig. 2F),
which is consistent with the immunofluorescence data above. In-
terestingly, 	75% of MTTDQ and 	85% of MDDDQ accumu-
lated in the saponin-soluble fraction (Fig. 2F), which suggested a
cytosolic accumulation of these mutants that could not be de-
tected by immunofluorescence analysis. Thus, these results con-
firm and expand the evidence that BAF phosphorylation affects its
subcellular distribution. Specifically, these data are consistent
with the model that BAF phosphorylation facilitates its cytosolic
accumulation, while complete BAF dephosphorylation leads to its
nuclear retention.
BAF hyperphosphorylation inhibits its dimerization. Struc-
tural studies of BAF have demonstrated its ability to ho-
modimerize and, in the presence of DNA molecules, to cross-
bridge DNA to form a higher-order nucleoprotein complex (2, 3,
42). In addition, functional studies of a BAF mutant with an in-
ability to form dimers showed that BAF dimerization contributes
to its DNA binding and is also necessary for its antipoxviral activ-
ity (29). However, the effect of phosphorylation on BAF’s ability
to homodimerize is currently unknown. To address this question,
lysates from CV1 cells expressing empty vector, WT, or BAF mu-
tants were subjected to anti-FLAG immunoprecipitation. These
immunoprecipitations were performed in the presence of nu-
clease to ensure that DNA was not available to augment BAF-BAF
interaction. Input lysates and immunoprecipitated fractions were
then subjected to immunoblotting with an anti-BAF antibody to
measure dimerization by assessing the coprecipitation of endoge-
nous BAF. As expected, WT BAF was able to coprecipitate endog-
enous BAF (Fig. 3). Similarly, MAAAQ and MTTDQ can also
coprecipitate endogenous BAF. Interestingly, only the fastest-mi-
grating (unphosphorylated) form of endogenous BAF was de-
tected in each of these immunoprecipitates, indicating that phos-
phorylation impairs dimerization of BAF. Consistent with this
model, no endogenous BAF was immunoprecipitated with
MDDDQ. Together, these data indicate for the first time that BAF
hyperphosphorylation inhibits its dimerization.
BAF hyperphosphorylation reduces its DNA binding activity
against transfected plasmid DNA and chromatin DNA. Building
on previous evidence that BAF phosphorylation at Ser4 resulted in
reduced affinity for DNA in vitro (28), we next sought to examine
whether the MTTDQ protein also exhibited reduced interaction
with DNA in cells. In parallel, we also wanted to test our hypoth-
esis that the “hyperphosphorylated” mutant MDDDQ would re-
sult in a complete loss of its DNA binding activity. To address
these goals, we examined the DNA binding activity of BAF mu-
tants via chromatin immunoprecipitation (ChIP) analysis. CV1
cells expressing empty-vector control, WT, or BAF mutants were
transfected with 150 ng pG8-Luc plasmid for 24 h and subse-
quently fixed with paraformaldehyde. This pG8-Luc plasmid con-
tains the promoter of the vaccinia virus G8R gene driving the
expression of a luciferase gene (23, 25). Our recent study utilizing
this plasmid demonstrated that pG8-Luc coprecipitates with BAF
in ChIP analysis (25), validating this plasmid as a source of foreign
DNA that can be bound by BAF. After harvest and lysis of fixed
cells, lysates were subjected to immunoprecipitation of FLAG-
tagged BAF followed by reverse cross-linking of protein-DNA
complexes and qPCR analysis. qPCR was performed on purified
DNA by using primers specific for either the G8 promoter region
or the GAPDH locus, which we used as a representative region of
nuclear chromatin (as described in reference 25). Fold enrichment
was calculated relative to an empty-vector control. From these
analyses, we found that WT BAF can interact with plasmid DNA
with a fold enrichment of140 (Fig. 4A). Similarly, MAAAQ also
interacts with plasmid DNA with a slightly higher fold enrichment
of 200 (Fig. 4A). In contrast, both MTTDQ and MDDDQ ex-
hibited little or no binding of plasmid DNA, with only 3.5- and
1.0-fold enrichment, respectively, which is 40- and 140-fold less
than that for the WT BAF (Fig. 4A). With respect to binding to
chromatin DNA, we found a similar trend of DNA binding. Spe-
cifically, MTTDQ and MDDDQ also did not interact with chro-
matin DNA, with20- to 25-fold less binding than for WT BAF
(Fig. 4B). In contrast, MAAAQ precipitated 3-fold more chroma-
tin DNA than the WT BAF (Fig. 4B).
To complement these ChIP data, we also performed immuno-
fluorescence analysis on these aforementioned cells that had been
transfected with plasmid DNA. This was done to assay the ability
of each BAF mutant to relocalize to cytoplasmic puncta contain-
ing foreign DNA, as previously established (29). Like endogenous
BAF’s relocalization to plasmid DNA (29), cells expressing WT
BAF also respond to the presence of foreign plasmid DNA by
forming numerous puncta throughout the cytoplasm (Fig. 4D,
arrowheads). Interestingly, although MAAAQ is clearly capable of
binding foreign DNA (Fig. 4A), the nuclear localization of this
protein appears to severely reduce its cytoplasmic binding ability
because the number of cytoplasmic puncta observed is less than
20% of what was observed with WT BAF (Fig. 4E). Finally, despite
the clear cytoplasmic presence of MTTDQ and MDDDQ, the
number of cytoplasmic puncta observed in either MTTDQ- or
MDDDQ-expressing cells is only 3% of that seen in WT BAF-
expressing cells (Fig. 4F and G). Altogether, we have shown that
BAF phosphorylation disrupts its DNA binding activity in live
cells, as evident from our studies of both phosphomimetics
MTTDQ and MDDDQ. In addition, Ser4 phosphorylation is
largely sufficient to inhibit DNA binding in these assays, since
similar effects were observed for both MTTDQ- and MDDDQ-
expressing cells. Finally, we have also shown that unphosphory-
lated BAF can interact with either chromatin DNA or plasmid
DNA, although its binding likely occurs predominantly in the
nucleus rather than the cytoplasm.
Both unphosphorylated and hyperphosphorylated BAF ex-
hibit a reduced ability to relocalize to vaccinia virus DNA upon
infection. Our current working model is that BAF’s antipoxvi-
ral activity depends on its ability to relocalize to viral replica-
tion factories in the cytoplasm and to bind and condense viral
FIG 3 Dimerization assay of BAF by immunoprecipitation (IP). Cell lysates
were subjected to immunoprecipitation using an anti-FLAG antibody fol-
lowed by Western blot analyses using anti-BAF antibody. Input lysates (left)
were also analyzed to illustrate the presence and migration pattern of endog-
enous BAF in each lysate. The bracket indicates the epitope-tagged BAF pro-
teins, while the arrowhead indicates endogenous BAF.
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DNA therein (27, 29). However, in the presence of the vaccinia
virus B1 kinase, BAF is phosphoinactivated, and no relocaliza-
tion of BAF is observed (27, 29). Building on these data, we
wanted to examine how relocalization of BAF during vaccinia
virus infection is impacted by its phosphorylation status. Based
on our earlier observations of the lack of DNA binding when
BAF is phosphorylated, we hypothesized that both phosphomi-
metic mutants MTTDQ and MDDDQ also lack the capability
to relocalize to viral DNA replication factories upon infection
with vaccinia virus. To address this hypothesis, we performed
immunofluorescence analysis on cells that were infected with
the Cts2 mutant vaccinia virus. The temperature-sensitive Cts2
mutant carries a point mutation in the B1 locus, resulting in the
production of an unstable and nonfunctional B1 protein at
nonpermissive temperatures (21, 22). For these studies, CV1
cells expressing empty-vector control, WT, or BAF mutants
were infected with Cts2 virus at an MOI of 5 at 32°C for 16 h,
followed by a shift to 40°C for 3 h. This temperature shift
protocol allows first for viral factory formation at the permis-
sive temperature, followed by arrest of viral DNA synthesis
at the nonpermissive temperature and potential BAF relocal-
ization to the cytoplasmic viral factories (22, 27). The colocal-
ization of BAF mutants and viral DNA replication factories was
then assessed by costaining cells with anti-FLAG (green) and
anti-I3 (red) antibodies (Fig. 5). I3 is a vaccinia virus single-
stranded DNA binding protein that is often found throughout
the cytosol but is highly enriched at active viral DNA replica-
tion sites, thus allowing us to identify those sites in this assay
(43–45). For example, our immunofluorescence analyses
showed that cells that were expressing the empty-vector con-
trol contained some I3 throughout the cell, but most was local-
ized to viral factories (Fig. 5A, arrowheads). These results are
indicative of normal infection and serve as a positive control.
Next, in 1 FLAG-WT BAF cells, while we observed a reduc-
tion in the number of I3 foci due to the increased amount of
WT BAF, the colocalization of FLAG-tagged BAF to the I3-
positive factories was often observed (Fig. 5B, arrows). Mean-
while, in MAAAQ-expressing cells, we observed I3 staining
similar to that in the control cells, with no obvious localization
of MAAAQ to the I3 sites in the cytoplasm (Fig. 5C, arrow-
heads). While this result is somewhat incongruent with the
data shown in Fig. 4E, the fact that MAAAQ could be detected
relocalizing to plasmid DNA in that assay may be due to the
larger amount of DNA introduced by transfection than by in-
fection. These data in Fig. 5C suggest that because MAAAQ is
localized predominantly in the nucleus, interaction between
the nucleus-retained MAAAQ proteins and the cytoplasmic
viral DNA likely becomes spatially restricted. Finally, in the
phosphomimetic MTTDQ- and MDDDQ-expressing cells, we
also observed I3 staining at multiple viral factories (Fig. 5D and
E, arrowheads), with little relocalization of these BAF mutant
proteins to the I3 sites (Fig. 5D and E, arrows). This is consis-
tent with our previous observation that, despite their cytoplas-
mic localization, the weakened DNA binding activities of these
two mutants likely limits their response to vaccinia virus.
BAF hyperphosphorylation mutants cannot suppress vac-
cinia virus DNA replication and yield. Based on the observation
that BAF phosphorylation led to the loss of DNA binding, we
posited that BAF phosphomimetic mutant proteins would not be
functional in responding to vaccinia virus infection. Specifically,
we hypothesized that neither the MTTDQ nor the MDDDQ will
disrupt viral DNA replication and/or productive infection of the
Cts2 virus. To accurately analyze the effect of BAF mutant pro-
teins on vaccinia virus, we expressed each BAF mutant in cells that
lack endogenous BAF. This was accomplished by first depleting
endogenous BAF using shRNA, followed by expression of shRNA-
resistant WT BAF or BAF mutant genes. Upon antibiotic selection
of these stable cell lines, their protein expression and growth char-
acteristics were assessed. Averaging from three independent trans-
duction events, we were able to express the BAF protein relative to
shControl in WT BAF by as much as 5.5-fold and either
FIG 4 DNA binding activity of WT BAF and its mutants to plasmid DNA. (A
and B) ChIP analyses of WT BAF and BAF mutants. Cells were transfected with
150 ng of pG8-Luc plasmid DNA for 24 h, followed by fixation, immunopre-
cipitation with anti-FLAG antibody, and reverse cross-linking of protein-DNA
complexes. Purified DNA was analyzed by qPCR using primers specific for the
G8 promoter region of pG8-Luc plasmid (A) or the GAPDH locus of chroma-
tin DNA (B). Fold enrichment was obtained relative to an empty-vector con-
trol and normalized to input DNA (n  3). Error bars represent standard
deviations. (C to G) Immunofluorescence analyses of cells indicated in panels
A and B that were transfected with 1 g pUC19 plasmid DNA prior to cell
costaining with an anti-FLAG antibody (Alexa Fluor 488 conjugated) and
DAPI. Cells expressing empty vector (C), WT BAF (D), MAAAQ (E), MTTDQ
(F), and MDDDQ (G) were analyzed. Scale bar, 50m. Puncta formations are
indicated by arrowheads.
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MTTDQ or MDDDQ by 3-fold (Fig. 6A). Furthermore, the
MTTDQ-shBAF and MDDDQ-shBAF cells displayed a growth
rate similar to that of the vector-shBAF control.
Next, we tested the ability of each BAF protein to repress vac-
cinia virus DNA replication and viral production. Control cells
(vector-shBAF), as well as WT BAF-shBAF, MTTDQ-shBAF, and
MDDDQ-shBAF cells were infected with WT or Cts2 vaccinia
virus at an MOI of 5 at 40°C for 24 h. Cells were then harvested and
utilized in parallel DNA replication or viral yield analyses. First,
viral DNA replication was measured by real-time qPCR. In our
positive control, WT vaccinia virus-infected cells showed compa-
rable viral DNA replication among all cells tested (Fig. 6B, gray
bars), which indicates that, regardless of the presence of mutant
BAF, these cells are susceptible to vaccinia virus infection and can
support viral DNA replication. In contrast, in Cts2-infected cells,
we observed a 57-fold reduction in viral DNA replication in WT
BAF-shBAF relative to control cells (Fig. 6B, black bars). This
confirms that the WT BAF protein is functional in suppressing
viral DNA replication during Cts2 infection. Interestingly, in Cts2
infection of cells expressing BAF phosphomimetic mutants, we
found that the repressive activity of each of these mutants was
significantly weaker than that of the WT BAF. Specifically, only a
partial reduction of viral DNA replication (10-fold) was observed
in MTTDQ-shBAF cells, and even less (2-fold) was found in
MDDDQ-shBAF cells compared to the vector-shBAF control
(Fig. 6B, black bars).
In parallel analyses, we also assayed viral production from the
same samples described above using a plaque titration assay. Dur-
ing WT vaccinia virus infection, viral production was comparable
among all cell lines tested, which is consistent with the DNA rep-
lication results shown above (Fig. 6C, gray bars). In Cts2-infected
cells, we observed a dramatic reduction in viral yield (90-fold) in
WT BAF-shBAF cells relative to that in control vector-shBAF cells
(Fig. 6C, black bars) which is also consistent with the DNA repli-
FIG5 Relocalization of BAF and its mutants to viral replication factories in B1-deficient Cts2 vaccinia virus-infected cells. (A to E) Immunofluorescence analyses
of cells stably expressing empty vector (A), WT BAF (B), MAAAQ (C), MTTDQ (D), and MDDDQ (E). Cells were infected with Cts2 vaccinia virus at an MOI
of 5 at 32°C for 16 h, followed by a shift to 40°C for 3 h. Cells were then costained with anti-FLAG antibody (Alexa Fluor 488 conjugated; green), anti-I3 antibody
(Alexa Fluor 594 conjugated; red), and DAPI (blue). Scale bar, 50m. In the rightmost panels (-FLAG
-I3), I3-positive FLAG-negative puncta are indicated
by arrowheads, and evidence of colocalization (I3-positive, FLAG-positive) sites are indicated by arrows.
Jamin et al.
5348 jvi.asm.org Journal of Virology
cation results. In contrast to the functional WT BAF, we found
only a partial reduction (8-fold) in viral yield in Cts2-infected
MTTDQ and even less reduction (4-fold) in MDDDQ cells com-
pared to control cells. These results confirm our hypothesis that
hyperphosphorylated BAF is nonfunctional against vaccinia virus
in a manner correlating with impaired DNA binding activity.
Unphosphorylatable BAF also cannot suppress vaccinia vi-
rus DNA replication and yield. The BAF nonphosphorylatable
mutant MAAAQ displays some interesting properties which
contrast with those of the other mutants we produced. It binds
DNA at least as efficiently as WT BAF, is predominantly nu-
clear, relocalizes to cytoplasmic puncta much less efficiently
than WT BAF upon introduction of foreign DNA, and did not
relocalize to cytoplasmic viral replication factories upon vac-
cinia virus infection. Based on these observations, we hypoth-
esized that despite possessing DNA binding activity and due to
its localization, MAAAQ would be nonfunctional against vac-
cinia virus. To address this question, we also expressed
MAAAQ in BAF-depleted cells (Fig. 7A) using the same
method described in the preceding section. Upon infection
with WT vaccinia virus, we found comparable viral DNA rep-
lication and virus production in MAAAQ-shBAF and control
vector-shBAF cells (Fig. 7B and C, gray bars). Interestingly,
with respect to Cts2 vaccinia virus infection, we found only a
very modest inhibition of viral DNA replication in MAAAQ-
shBAF cells (3-fold) relative to control cells, which was20-
fold less inhibition than in WT BAF-shBAF cells (Fig. 7B, black
bars). This indicates that MAAAQ does not repress viral DNA
FIG 6 Phosphomimetic mutants MTTDQ and MDDDQ minimally suppress
Cts2 viral DNA replication and viral production. (A) Western blot analyses of
cells stably expressing vector-shControl and vector-shBAF, WT BAF-shBAF,
or BAF mutant-shBAF. Protein expression was detected with anti-FLAG, anti-
BAF, or anti-GAPDH antibody. Endogenous BAF proteins are indicated by
arrowheads, and FLAG-tagged proteins are indicated by a bracket. (B and C)
Cells from panel A, with the exception of vector-shControl, were infected with
WT (gray bars) or Cts2 (black bars) virus at an MOI of 5 at 40°C for 24 h.
Following harvest, cells were analyzed for viral DNA replication (B) or viral
production (C). (B) qPCR were performed by using vaccinia DNA-specific
primers, and viral DNA replication was measured relative to the vector-shBAF
control (n  3). (C) Viral titer was measured by plaque titration assay on
BSC40 cells at 32°C (n 3). Error bars represent standard deviations (***, P
0.005 from unpaired t test analysis).
FIG 7 Nonphosphorylatable mutant MAAAQ does not suppress Cts2 vac-
cinia viral DNA replication and viral production. (A) Western blot analyses of
cells stably expressing vector-shControl, vector-shBAF, WT BAF-shBAF, and
MAAAQ-shBAF. Protein expression was detected with anti-FLAG, anti-BAF,
or anti-GAPDH antibody. Endogenous BAF proteins are indicated by arrow-
heads, and FLAG-tagged proteins are indicated by bracket. (B and C) Cells
from panel A, with the exception of vector-shControl, were infected with WT
or Cts2 vaccinia virus at an MOI of 5 at 40°C for 24 h. Following harvest, cells
were analyzed for viral DNA replication (B) or viral production (C). (B) qPCR
was performed by using vaccinia virus DNA-specific primers, and viral DNA
replication in either WT or Cts2 infection was measured relative to the vector-
shBAF control (n 3). (C) Viral titer was measured by plaque titration assay
on BSC40 cells at 32°C (n 3). Error bars represent standard deviations (***,
P 0.005 from unpaired t test analysis).
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replication as efficiently as WT BAF does. In addition, we
found only partial reduction in the viral yield of Cts2-infected
MAAAQ-shBAF cells (7.5-fold) relative to control cells, as op-
posed to the 90-fold reduction in WT BAF-shBAF cells (Fig.
7C, black bars). Overall, these analyses confirm our hypothesis
that the predominantly nuclear unphosphorylated BAF, de-
spite its ability to bind DNA, is only minimally effective at
inhibiting vaccinia viral DNA replication and new virus pro-
duction compared to WT BAF.
Phosphatase inhibitor treatment leads to BAF relocalization
from the nucleus to the cytoplasm. Our data above demonstrate
that phosphorylation of BAF is necessary for its cytoplasmic
localization; however, constitutively phosphorylated BAF is
unable to act as a host defense against poxviral DNA replica-
tion. This leads us to posit that WT BAF is dephosphorylated in
the cytoplasm to “activate” its antiviral activity. In support of
this model, it has recently been observed that at least two phos-
phatases, PP2A and PP4, can act on BAF (32, 34). Those studies
showed that siRNA-mediated depletion of the catalytic subunit
of either PP2A or PP4 led to the accumulation of hyperphos-
phorylated BAF in cell culture and C. elegans (32, 34). Therefore,
we tested whether BAF phosphatases were capable of modulating
BAF phosphorylation, localization, or antipoxviral activity in our
cell system. Our first aim was to confirm the involvement of phos-
phatases in affecting BAF’s phosphorylation via treatments with
phosphatase inhibitors. This method is advantageous since the
effects of inhibitors are rapid and the substrates are largely known.
Our initial study was to determine the minimal time in which BAF
becomes completely phosphorylated. CV1 cells were treated for a
period of 15 min up to 3 h with a 50 nM concentration of the
phosphatase inhibitor calyculin A. Calyculin A is a potent inhibi-
tor of PP1 and PP2A and is a useful tool to demonstrate the in-
volvement of these phosphatases in cell culture systems (46). In
this analysis, we observed an increase in BAF phosphorylation
after 1 h of drug treatment and complete hyperphosphorylation
(as judged from the disappearance of the fastest-migrating form of
BAF) upon 2 h of treatment (Fig. 8A). Next, to determine the
dose-dependent response of calyculin A and its effects on BAF’s
subcellular distribution, CV1 cells were treated with 12.5, 25, 50,
or 100 nM calyculin A at 37°C for 2 h, followed by subcellular
fractionation with 0.5% saponin (cytoplasmic fraction) and sub-
sequently with 0.5% Triton X-100 (nuclear fraction). The degree
of BAF phosphorylation was analyzed by immunoblot analysis
using an anti-BAF antibody. In DMSO control-treated cells, dif-
ferent BAF species were present in both the cytosol and the nuclear
fractions (Fig. 8B). Upon calyculin A treatment, we observed an
increase in the amount of phosphorylated BAF at 25 nM and com-
plete BAF hyperphosphorylation at 50 nM, followed by a clear
shift in protein distribution from the nuclear to the cytoplasmic
fraction (Fig. 8B). Specifically,65% of BAF accumulated in the
cytosol at 25 nM and88% of BAF was present in the cytosol at 50
nM, as opposed to the35% of BAF found in the cytosol with the
DMSO control (Fig. 8C). As a complement to these analyses, we
also treated CV1 cells with okadaic acid, another natural inhibitor
of PP1 and PP2A (47), and found increasing BAF phosphorylation
in a dose-dependent manner, along with a clear shift in BAF’s
distribution to the cytosol as it becomes phosphorylated (data not
shown). Overall these results suggest that BAF is the target of
calyculin A and an okadaic acid-sensitive phosphatase(s) and
demonstrate for the first time the impact of BAF dephosphoryla-
tion in regulating its subcellular distribution.
PP2A is involved in dephosphorylating BAF and can coun-
teract B1 activity on BAF in vaccinia virus-infected cells. Al-
though the use of calyculin A and okadaic acid clearly upregulated
BAF phosphorylation, we noticed that extended treatment with
these inhibitors was cytotoxic. These effects have been previously
reported in cell cultures and have been linked to global effects of
phosphatase inhibition on cytoskeleton actin and myosin phos-
phorylation (48–50). Therefore, we pursued the possibility of tar-
geting an individual phosphatase(s) in an effort to reduce the pos-
sibility of pleiotropic effects in our system. To this end, we
knocked down several phosphates using siRNA oligonucleotides
directed against PP1, PP2A, PP4, and PP6. Briefly, cells were
transfected with a 50 nM concentration of each siRNA for 72 h,
and protein depletions were measured by immunoblotting using
antibodies specific to each phosphatase. In some cases, we also
measured the mRNA transcript levels by qPCR following 48 h
posttransfection. First, we analyzed the depletion of PP1 isoforms
, , and . Despite efficient depletion of each isoform, we found
no changes in BAF phosphorylation profiles in these cells com-
pared to control cells (data not shown). The same was also true in
FIG 8 Calyculin A treatment promotes BAF relocalization to the cytosol. (A)
Time-dependent analyses of BAF phosphorylation upon calyculin A treatment
of CV1 cells. Cells were treated with 1% DMSO or 50 nM calyculin A at 37°C
for the indicated times. Western blot analysis was performed using anti-BAF
and anti-tubulin (loading control) antibodies. (B) Dose-dependent response
and subcellular fractionation of CV1 cells treated with calyculin A. Cells were
treated with the indicated concentration of calyculin A at 37°C for 2 h, fol-
lowed by subcellular fractionation into cytosolic (c) and nuclear (n) fractions.
Western blot analysis was performed by using anti-BAF antibody. (C) The
percent protein distribution was calculated based on Western blot results from
panel B. Error bars represent standard deviations. All data were obtained from
three independent experiments.
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cells that were depleted of all 3 PP1 isoforms, which suggests that
PP1 likely does not play a role in BAF dephosphorylation in CV1
cells. Next, we depleted the catalytic subunit of PP2A, PP4, or PP6.
In cells that were depleted of PP2A, we found an increased amount
of phosphorylated BAF (Fig. 9A). However, neither the PP4 nor
the PP6 depletion enhanced BAF phosphorylation levels despite
efficient depletion of each of these phosphatases (data not shown).
Furthermore, codepletion of PP2A, PP4, and PP6 also did not
result in additional enhancement of BAF phosphorylation com-
pared to that in cells depleted of PP2A alone (data not shown).
Thus, these studies show that PP2A is involved in dephosphory-
lating BAF in CV1 cells, as has been demonstrated in HeLa cells
(32), while no evidence could be found that PP1, PP4, or PP6
targets BAF in this model system.
Since BAF phosphorylation by the B1 kinase occurs during
vaccinia virus infection, we raised the question of whether BAF
dephosphorylation by cellular PP2A may counteract B1 activity.
Thus, we hypothesize that in the absence of PP2A, BAF phosphor-
ylation in vaccinia virus-infected cells would increase. To test this,
CV1 cells were transfected with 50 nM control, PP2A, or PP4
siRNA for 72 h at 37°C, followed by infection with WT or Cts2
virus at an MOI of 5 at 40°C for 24 h. Total cell lysates were then
analyzed by immunoblot analysis using anti-BAF and anti-phos-
pho-BAF (specific for phosphorylated Ser4) antibodies. First, as a
control, in the absence of PP2A depletion, we observed an increase
in the Ser4 phosphorylation in cells that were infected with WT
vaccinia virus (Fig. 9B, lane 2) compared to uninfected control
cells (Fig. 9B, lane 1). This is consistent with the activity of B1 in
phosphorylating BAF upon infection. In contrast, there was only a
slight change in BAF phosphorylation in Cts2 vaccinia virus-in-
fected cells (Fig. 9B, lane 6), which is consistent with the lack of
active B1 expressed from this virus. Next, upon infections of cells
that were depleted of PP2A, we observed increased hyperphos-
phorylation of BAF in WT vaccinia virus-infected cells (Fig. 9B,
lane 3). This suggests that PP2A can play a role in counteracting B1
kinase activity on BAF. Meanwhile, we also observed an increase
in phosphorylated BAF in PP2A-depleted cells that were infected
with Cts2 vaccinia virus (Fig. 9B, lane 7). In addition, we also
tested BAF phosphorylation in PP4-depleted cells infected with
either WT or Cts2 vaccinia virus and found no changes in BAF
phosphorylation patterns (Fig. 9B, compare lanes 2 and 4 or lanes
6 and 8).
Treatment of cells with siPP2A is not sufficient to rescue Cts2
viral DNA replication/yield. Because PP2A depletion in infected
cells led to an increase in BAF phosphorylation, we hypothesized
that this increase in phosphorylation may enhance vaccinia viral
DNA replication and viral production, especially in Cts2 vaccinia
virus-infected cells. To test this, CV1 cells were transfected with 50
nM control or PP2A siRNA for 72 h at 37°C, followed by infection
with WT or Cts2 virus at an MOI of 5 at 40°C for 24 h. Following
harvest of cells, qPCR was performed on viral DNA isolated from
infected cells. In WT vaccinia virus-infected cells, we observed
FIG 9 PP2A depletion is not sufficient to rescue Cts2 vaccinia viral DNA replication. (A) CV1 cells were treated with 50 nM control or PP2A siRNA at 37°C for
72 h. Whole-cell lysates were used for Western blot analyses using anti-BAF or anti-PP2A antibodies. Bands shown were all taken from the same blot with the
same exposure times; however, some irrelevant lanes have been removed for clarity. (B) Western blot analysis of BAF phosphorylation in various cell treatments.
CV1 cells were transfected with 50 nM control, PP2A, or PP4 siRNA at 37°C for 72 h. Cells were then infected with WT or Cts2 vaccinia virus at an MOI of 5 at
40°C for 24 h. Western blot analyses were performed using the indicated antibodies. (C) Viral DNA replication of CV1 cells transfected with 50 nM control or
PP2A siRNA at 37°C for 72 h followed by infection with WT (gray bars) or Cts2 (black bars) virus at an MOI of 5 at 40°C for 24 h. qPCR was performed on purified
DNA by using vaccinia virus DNA-specific primers. Viral DNA replication was calculated relative to control siRNA in each infection set (n  3). Error bars
represent standard deviations. (D) Model of BAF phosphoregulation by cellular and viral enzymes. Filled arrows indicate movement of BAF proteins within the
cell, while open arrows indicate BAF’s (de)phosphorylation by cellular and viral enzymes.
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similar viral DNA replication in control and PP2A-depleted cells,
as we expected (Fig. 9C, gray bars). In Cts2-infected cells, rather
than a rescue of DNA replication, we observed a slight reduction
(2-fold) in viral DNA replication in PP2A-depleted cells relative to
the control cells (Fig. 9C, black bars). Overall, these results show
that BAF-induced phosphorylation via PP2A depletion is not suf-
ficient to enhance Cts2 viral DNA replication. These results either
may be explained by our inability to completely deplete PP2A
from cells, thus leaving some enzyme to activate BAF, or suggest
the existence of another, unknown BAF phosphatase which can
activate BAF.
DISCUSSION
As a DNA binding protein with important functions in mitosis,
the antiviral response, and likely other cellular processes, it is nec-
essary that BAF is tightly regulated. In recent years, it has become
increasingly evident that dynamic phosphorylation is likely a key
contributor to BAF’s regulation. Indeed, phosphorylation has
been clearly demonstrated to affect multiple molecular properties
of BAF in vitro, including its DNA binding activity and its inter-
action with LEM proteins (28, 35). A link between BAF phosphor-
ylation by the kinase VRK1 and its presence in the cytoplasm has
also been discovered, suggesting that modification of BAF can
control its localization as well. Despite this evidence of the impor-
tance of the phosphoregulation of BAF, much remains to be
learned about how phosphorylation modulates BAF properties in
live cells and in response to infection. In this study, we assessed the
effects of BAF phosphorylation on multiple BAF properties, in-
cluding DNA binding, BAF dimerization, and localization. As a
model of constitutive phosphorylation or dephosphorylation, we
generated and analyzed cells stably expressing BAF phosphoryla-
tion mutants: phosphomimetic MTTDQ and MDDDQ and un-
phosphorylatable MAAAQ mutants. These mutants served as
powerful tools in studying the direct effects of BAF phosphoryla-
tion. Ultimately, our goal was to better understand how phos-
phorylation coordinately regulates several BAF properties likely
required for its antipoxviral activity, while simultaneously gaining
insights into how BAF is regulated in uninfected cells.
In most cell types, BAF localizes to the nucleus, the cytoplasm,
and the nuclear envelope, although its relative level at each of these
locations can be cell type and age dependent (40). From our ex-
amination of the BAF phosphomimetic mutants, we found that
phosphorylated BAF shifts markedly from the nucleus to the sa-
ponin-soluble cytosolic fraction in comparison to WT BAF. We
observed this localization change not only in CV1 cells as we de-
scribed here but also in other cell types, including mouse fibro-
blast L929 cells and HeLa cells (data not shown), suggesting that
the regulation of BAF localization through phosphorylation is
conserved across species and cell lines. Furthermore, we consis-
tently found that the unphosphorylatable mutant MAAAQ is
highly concentrated in the nucleus in CV1 cells as shown here, as
well as in L929 and HeLa cells (data not shown). These findings
confirm and significantly extend prior evidence that BAF phos-
phorylation leads to changes in its localization. For example, tran-
sient expression of BAF-S4E in HeLa cells (35) and of GFP-BAF/
VRK1 in U2OS cells (28) first suggested that BAF phosphorylation
alters the protein’s localization in the cell. Meanwhile, studies of
BAF-MAAAQ in Drosophila oocytes (33) and VRK1 depletion in
C. elegans embryo and breast cancer cell lines (30, 31) also indi-
cated that dephosphorylated BAF becomes less mobile in the nu-
cleus. Thus, our data are consistent with these reports and form
the basis for our working model (Fig. 9D) that BAF phosphoryla-
tion mobilizes the protein, allowing it to relocalize within the nu-
cleus or to transit to the cytoplasm. At this time, it remains to be
determined whether BAF’s movement between nucleus and cyto-
plasm occurs via active transport or passive diffusion through the
nuclear pore complex. However, BAF’s small size and lack of a
canonical nuclear localization sequence suggest that diffusion
may be a likely possibility.
Mobilization of BAF likely requires disruption of its protein-
DNA and/or protein-protein interactions (2). Indeed, BAF’s abil-
ity to interact with the LEM protein emerin is impaired by phos-
phorylation (35). However, while BAF has been known to form
homodimers for some time, to date no report has yet examined
the impact of BAF phosphorylation on its homodimerization.
Here we demonstrate that hyperphosphorylated BAF (from our
studies of MDDDQ) exhibits a sharply reduced ability to interact
with endogenous BAF. Interestingly, our study also indicates that
Ser4-phosphorylated BAF (MTTDQ) was still capable of immu-
noprecipitating endogenous BAF, leading us to speculate that
phosphorylation of both Thr residues (or all residues, including
Ser4) may be required to impact BAF-BAF interaction. Together,
these data demonstrate for the first time that like BAF’s interaction
with a LEM domain partner, its homodimeric interaction is also
phosphoregulated. As current structural studies of BAF show no
direct contact between its sites of phosphorylation and its
dimerization interface (3, 51), additional studies will be needed to
determine how phosphorylation might modulate BAF-BAF con-
tacts.
Based on both direct in vitro studies (28) and indirect evi-
dence in live cells (30–33), phosphorylation is a potent inhib-
itor of BAF interaction with DNA. Here, we have examined
BAF-DNA interaction of our mutant proteins by utilizing a
ChIP protocol. This approach allows us to monitor how phos-
phorylation regulates BAF binding to cellular chromatin DNA
as well as to foreign plasmid DNA in a more direct and quan-
titative manner than was previously possible. In these ChIP
analyses, we found that BAF phosphorylation abolishes its
DNA binding activity independent of the DNA sequence or
sources (chromatin DNA versus plasmid DNA). Consistent
with these results, our immunofluorescence analyses also
showed significantly reduced relocalization of phosphorylated
BAF to transfected plasmid DNA puncta in the cytoplasm. It is
worth noting that the similar DNA binding inhibition observed
for MTTDQ and MDDDQ suggests that Ser4 phosphorylation
is the major contributor to the regulation of BAF’s DNA bind-
ing activity. Together with previous reports demonstrating
Ser4 phosphorylation by both VRK1 and B1 kinase (28, 31), the
data shown here continue to support the model that VRK1/B1-
mediated BAF phosphorylation releases BAF from the DNA, as
first proposed by Nichols et al. (28). Finally, our ChIP experi-
ments revealed a modest but detectable increase in the chro-
matin DNA bound to MAAAQ compared to the WT BAF. En-
hanced chromatin binding by unphosphorylated BAF is also
likely to contribute to the reduced mobility of BAF observed by
other researchers and probably influences BAF’s subcellular
localization by limiting its movement within and out of the
nucleus.
If it is correct that BAF phosphorylation releases it from the
DNA and mobilizes it out of the nucleus, it would result in an
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increased proportion of phosphorylated BAF in the cytosol. In this
event, we posited that Cts2 vaccinia viral DNA replication would
be enhanced, since the cytoplasmic pool of phosphorylated BAF
would be incapable of binding viral DNA. Indeed, we found that
the cytoplasmic hyperphosphorylated BAF pool, as shown in
MDDDQ, was unable to suppress Cts2 viral DNA replication
(only a 2-fold reduction) as well as viral production (4-fold reduc-
tion) as opposed to the WT BAF activity of 50-fold reduction in
viral DNA replication and 90-fold reduction in viral production.
Somewhat surprisingly, despite a clear loss in MTTDQ DNA bind-
ing activity shown by ChIP analysis, we found that MTTDQ could
still partially suppressed Cts2 viral DNA replication (10-fold re-
duction) as well as viral production (8-fold reduction). Thus, in
the absence of phosphorylated Thr residues, BAF remains capable
of antipoxviral defense, albeit much more weakly than WT BAF.
Importantly, with respect to the unphosphorylatable MAAAQ
mutant, we found that it was incapable of suppressing viral DNA
replication (2.5-fold reduction) compared to the WT BAF ac-
tivity (50-fold reduction) and could only partially suppress pro-
duction of new virus. Therefore, although unphosphorylated BAF
has DNA binding activity, its localization likely restricts its activity
to the nucleus, allowing Cts2 viral DNA replication to continue
unhindered in the cytoplasm. This demonstrates that the cellular
localization of BAF also is a critical determinant of its antiviral
activity against vaccinia virus, which forms the basis for our model
that BAF must be only transiently phosphorylated to reach the
cytoplasm and interfere with the viral life cycle (Fig. 9D).
As discussed above, phosphorylation enhances the fraction of
BAF present in the cytosol, which would suggest that phosphory-
lated BAF would be the predominant form of BAF in that com-
partment. However, our Western blot analyses of total BAF in the
cytoplasm showed equal amounts of modified and unmodified
BAF, as assessed by the fractions of shifted and unshifted BAF.
This observation suggested that a cytoplasmic BAF phosphata-
se(s) may exist. Additionally, while the phosphorylation of BAF is
needed for its cytoplasmic localization, phosphomimetic mutants
representing constitutively phosphorylated forms of BAF are un-
able to act as a host defense against vaccinia virus. The presence of
a cytoplasmic BAF phosphatase would thus also explain how WT
BAF can be dephosphorylated as needed to bind viral DNA. We
therefore examined how phosphatase activity may regulate BAF’s
localization and antiviral activity. Indeed, when CV1 cells were
treated with phosphatase inhibitor, increased accumulation of hy-
perphosphorylated BAF correlating with increased inhibitor con-
centration could be observed. While these experiments were on-
going, it was discovered that BAF dephosphorylation can be
mediated by two phosphatases, PP2A and PP4 (32, 34). In this
study, we validated that PP2A is a BAF phosphatase and that upon
its depletion, phosphorylated BAF accumulated in our CV1 cells
as has been described previously (32). PP2A is proposed to act on
BAF during mitotic exit (32); however, it is also possible that PP2A
can dephosphorylate BAF following its modification by the B1
kinase upon vaccinia virus infection. This appears to be true, as
depletion of PP2A led to accumulation of hyperphosphorylated
BAF in cells that were infected with WT vaccinia virus. This dem-
onstrates for the first time that PP2A can counteract the B1-in-
duced phosphorylation of BAF. Next, we examined the impact of
PP2A depletion during Cts2 infection. Indeed, by depleting PP2A
in cells that were infected with B1-deficient Cts2 vaccinia virus, we
were able to increase BAF Ser4 phosphorylation. Despite this
phosphorylation increase, however, viral DNA replication was rel-
atively unchanged. Thus, in this case, PP2A depletion was not
sufficient to enhance Cts2 viral DNA replication. We speculate
that the incomplete depletion of PP2A may allow for residual
PP2A activity capable of dephosphorylating BAF in the cytoplasm
or that another BAF phosphatase also acts on BAF in the cyto-
plasm. As PP4 depletion by siRNA has been shown to increase
BAF phosphorylation in HEK293 cells (34), we examined it as a
candidate in our system. However, we could not obtain any evi-
dence that PP4 can act as a BAF phosphatase in our CV1 cell
model. It is possible that the different cell lines utilized in the study
by Zhuang et al. (34) versus our own may explain the differences
in our observations.
To summarize, these data demonstrate that dynamic phos-
phorylation plays a pivotal role in maintaining a balance of
BAF in the nucleus versus the cytoplasm, where it can interfere
with poxvirus infection. BAF localization is likely modulated in
part through alteration of its interaction with DNA and protein
partners, which we demonstrate are both disrupted by phos-
phorylation. These data shed further light on mechanisms em-
ployed by cellular kinase such as VRK1 or the vaccinia virus
kinase B1 to regulate BAF’s functions in mitosis and antiviral
host defense. Finally, as phosphorylation clearly regulates BAF
at multiple levels, it is tempting to speculate that it also impacts
other cellular processes recently associated with BAF, such as
transcriptional regulation (5, 8, 52, 53) and the DNA damage
response (6, 9, 54).
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